Private Market View

Zhuorun Biotechnology

Shenzhen, China · Founded 2019 · Privately Held (backing)

Last price · $/share
Implied valuation
$51.4M
Total raised
Last round

Key facts

  • Zhuorun Biotechnology’s last known valuation is $51.4M (Oct 2023).
  • Notable investors include Shenzhen Capital Group, Yhlo.
  • Status: Privately Held (backing).
Free account
See the evidence behind this price
  • ·The complete investor list — 2 names
  • ·Watchlist + deal alerts for Zhuorun Biotechnology
  • ·The full record, as it builds
Create free account
No card required

Funding rounds

No rounds on record

No funding rounds for Zhuorun Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About Zhuorun Biotechnology

Manufacturer of in vitro diagnostic products intended for the biopharmaceutical industry. The company's range of products includes single-use chemiluminescence immunoassay analysers, immunodiagnostic reagents, fluorescence immunochromatography kits, chemiluminescence detection systems, and microfluidic diagnostic platforms, thereby supporting accurate, rapid and scalable diagnostic testing.

Sector
Healthcare
HQ
Shenzhen, China
Founded
2019
Employees
180
Ownership
Privately Held (backing)
PA Mark — not yet priced

Zhuorun Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in Zhuorun Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on Zhuorun Biotechnology in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.